Intraocular pressure-lowering efficacy and safety of bimatoprost 0.03% therapy for primary open-angle glaucoma and ocular hypertension patients in China

详细信息    查看全文

• 作者：Kaidi Wang (1)
  Li Xu (2)
  Zhilan Yuan (3)
  Ke Yao (4)
  Junmei Zhao (5)
  Liang Xu (6)
  Aiwu Fang (7)
  Mingzhi Zhang (8)
  Lingling Wu (9)
  Jian Ji (10)
  Jiamin Hou (11)
  Qing Liu (12)
  Xinghuai Sun (1)
  
• 关键词：Bimatoprost ; Glaucoma ; Ocular hypertension ; Intraocular pressure ; Conjunctival hyperemia
• 刊名：BMC Ophthalmology
• 出版年：2014
• 出版时间：December 2014
• 年：2014
• 卷：14
• 期：1
• 全文大小：440 KB
• 参考文献：1. Varma R, Lee PP, Goldberg I, Kotak S: An assessment of the health and economic burdens of glaucoma. / Am J Ophthalmol 2011, 152:515-22. CrossRef
  2. Quigley HA, Broman AT: The number of people with glaucoma worldwide in 2010 and 2020. / Br J Ophthalmol 2006, 90:262-67. CrossRef
  3. AGIS Investigators: The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. / Am J Ophthalmol 2000, 130:429-40. CrossRef
  4. Kass MA, Heuer DK, Higginbotham EJ, Johnson CA, Keltner JL, Miller JP, Parrish RK 2nd, Wilson MR, Gordon MO: The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. / Arch Ophthalmol 2002, 120:701-13. CrossRef
  5. Leske MC, Heijl A, Hussein M, Bengtsson B, Hyman L, Komaroff E, Early Manifest Glaucoma Trial Group: Factors for glaucoma progression and the effect of treatment: the early manifest glaucoma trial. / Arch Ophthalmol 2003, 121:48-6. CrossRef
  6. Ederer F, Gaasterland DA, Dally LG, Kim J, VanVeldhuisen PC, Blackwell B, Prum B, Shafranov G, Allen RC, Beck A, AGIS Investigators: The Advanced Glaucoma Intervention Study (AGIS): 13. Comparison of treatment outcomes within race: 10-year results. / Ophthalmology 2004, 111:651-64. CrossRef
  7. Musch DC, Gillespie BW, Niziol LM, Lichter PR, Varma R, CIGTS Study Group: Intraocular pressure control and long-term visual field loss in the collaborative initial glaucoma treatment study. / Ophthalmology 2011, 118:1766-773. CrossRef
  8. Ishida N, Odani-Kawabata N, Shimazaki A, Hara H: Prostanoids in the therapy of glaucoma. / Cardiovasc Drug Rev 2006, 24:1-0. CrossRef
  9. Patil AJ, Vajaranant TS, Edward DP: Bimatoprost—a review. / Expert Opin Pharmacother 2009, 10:2759-768. CrossRef
  10. Konstas AG, Katsimbris JM, Lallos N, Boukaras GP, Jenkins JN, Stewart WC: Latanoprost 0.005% versus bimatoprost 0.03% in primary open-angle glaucoma patients. / Ophthalmology 2005, 112:262-66. CrossRef
  11. Orzalesi N, Rossetti L, Bottoli A, Fogagnolo P: Comparison of the effects of latanoprost, travoprost, and bimatoprost on circadian intraocular pressure in patients with glaucoma or ocular hypertension. / Ophthalmology 2006, 113:239-46. CrossRef
  12. Stewart WC, Konstas AG, Nelson LA, Kruft B: Meta-analysis of 24-hour intraocular pressure studies evaluating the efficacy of glaucoma medicines. / Ophthalmology 2008, 115:1117-122. CrossRef
  13. Noecker RS, Dirks MS, Choplin NT, Bernstein P, Batoosingh AL, Whitcup SM, Bimatoprost/Latanoprost Study Group: A six-month randomized clinical trial comparing the intraocular pressure-lowering efficacy of bimatoprost and latanoprost in patients with ocular hypertension or glaucoma. / Am J Ophthalmol 2003, 135:55-3. CrossRef
  14. Parrish RK, Palmberg P, Sheu WP, XLT Study Group: A comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: a 12-week, randomized, masked-evaluator multicenter study. / Am J Ophthalmol 2003, 135:688-03. CrossRef
  15. Cantor LB, Hoop J, Morgan L, Wudunn D, Catoira Y, Bimatoprost-Travoprost Study Group: Intraocular pressure-lowering efficacy of bimatoprost 0.03% and travoprost 0.004% in patients with glaucoma or ocular hypertension. / Br J Ophthalmol 2006, 90:1370-373. CrossRef
  16. Aptel F, Cucherat M, Denis P: Efficacy and tolerability of prostaglandin analogs: a meta-analysis of randomized controlled clinical trials. / J Glaucoma 2008, 17:667-73. CrossRef
  17. Kammer JA, Katzman B, Ackerman SL, Hollander DA: Efficacy and tolerability of bimatoprost versus travoprost in patients previously on latanoprost: a 3-month, randomised, masked-evaluator, multicentre study. / Br J Ophthalmol 2010, 94:74-9. CrossRef
  18. Faridi UA, Saleh TA, Ewings P, Venkateswaran M, Cadman DH, Samarasinghe RA, Vodden J, Claridge KG: Comparative study of three prostaglandin analogues in the treatment of newly diagnosed cases of ocular hypertension, open-angle and normal tension glaucoma. / Clin Exp Ophthalmol 2010, 38:678-82. CrossRef
  19. Huang HL, Sun XH, Xiao M: Comparison of intraocular pressure reducing effects of three prostaglandin eyedrops in open-angle glaucoma. / Zhonghua Yan Ke Za Zhi 2011, 47:109-13.
  20. Curran MP: Bimatoprost: a review of its use in OAG and ocular hypertension. / Drugs Aging 2009, 26:1049-071. CrossRef
  21. Katz LJ, Cohen JS, Batoosingh AL, Felix C, Shu V, Schiffman RM: Twelve-month, randomized, controlled trial of bimatoprost 0.01%, 0.0125%, and 0.03% in patients with glaucoma or ocular hypertension. / Am J Ophthalmol 2010, 149:661-71. CrossRef
  22. Chen MJ, Chen YC, Chou CK, Hsu WM: Comparison of the effects of latanoprost and bimatoprost on intraocular pressure in chronic angle-closure glaucoma. / J Ocul Pharmacol Ther 2007, 23:559-66. CrossRef
  23. European Glaucoma Society: Terminology and Guidelines for Glaucoma (3rd Edition). http://www.eugs.org/eng/EGS_guidelines.asp
  24. Geringer C, Imami N: Medical management of glaucoma. / Int Ophthamol Clin 2008, 48:115-41. CrossRef
  25. Coleman AL, Miglior S: Risk factors for glaucoma onset and progression. / Surv Ophthalmol 2008,53(Suppl 1):S3-0. CrossRef
  26. Heijl A, Leske MC, Bengtsson B, Hyman L, Bengtsson B, Hussein M, Early Manifest Glaucoma Trial Group: Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. / Arch Ophthalmol 2002, 120:1268-279. CrossRef
  27. Chauhan BC, Mikelberg FS, Balaszi AG, LeBlanc RP, Lesk MR, Trope GE, Canadian Glaucoma Study Group: Canadian Glaucoma Study: 2. risk factors for the progression of open-angle glaucoma. / Arch Ophthalmol 2008, 126:1030-036. CrossRef
  28. Quinones R, Earl ML: The efficacy of bimatoprost 0.03% monotherapy in patients previously using topical beta-blocker monotherapy for the treatment of glaucoma or ocular hypertension. / Adv Ther 2004, 21:370-79. CrossRef
  29. Feuerhake C, Buchholz P, Kimmich F: Efficacy, tolerability and safety of the fixed combination of bimatoprost 0.03% and timolol 0.5% in a broad patient population: multicenter, open-label observational study. / Curr Med Res Opin 2009, 25:1037-043. CrossRef
  30. Sonty S, Donthamsetti V, Vangipuram G, Ahmad A: Long-term IOP lowering with bimatoprost in open-angle glaucoma patients poorly responsive to latanoprost. / J Ocul Pharmacol Ther 2008, 24:517-20. CrossRef
  31. Ichhpujani P, Katz LJ, Hollo G, Shields CL, Shields JA, Marr B, Eagle R, Alvim H, Wizov SS, Acheampong A, Chen J, Wheeler LA: Comparison of human ocular distribution of bimatoprost and latanoprost. / J Ocul Pharmacol Ther 2012, 28:134-45. CrossRef
  32. Walt JG, Lee JT: A cost-effectiveness comparison of bimatoprost versus latanoprost in patients with glaucoma or ocular hypertension. / Surv Ophthalmol 2004,49(Suppl 1):S36-4. CrossRef
  33. Gao Y, Wu L, Li A: Daily cost of glaucoma medications in China. / J Glaucoma 2007, 16:594-97. CrossRef
  34. Wanichwecha-Rungruang B, Iemsomboon W: Efficacy and safety of bimatoprost for the treatment of open-angle glaucoma and ocular hypertension: a three-month, open-label study in community-based practices in Thailand. / J Med Assoc Thai 2005, 88:1228-235.
  35. Quinones R, Severin T, Mundorf T: Efficacy of bimatoprost 0.03 percent in untreated glaucoma and ocular hypertension patients: results from a large community-based clinical trial. / J Ocul Pharmacol Ther 2004, 20:115-22. CrossRef
  36. Whitson JT, Trattler WB, Matossian C, Williams J, Hollander DA: Ocular surface tolerability of prostaglandin analogs in patients with glaucoma or ocular hypertension. / J Ocul Pharmacol Ther 2010, 26:287-92. CrossRef
  37. Alag?z G, Bayer A, Boran C, Serin D, Kükner A, El?io?lu M: Comparison of ocular surface side effects of topical travoprost and bimatoprost. / Ophthalmologica 2008, 222:161-67. CrossRef
  38. Ge J, Sun XH, Wang NL, Zhao JL, Wu LL, Chen XM, Wang ZX, Li B: Intraocular pressure lowering efficacy and safety of travoprost 0.004% as a replacement therapy in patients with open angle glaucoma or ocular hypertension. / Chin Med J (Engl) 2010, 123:1417-421.
  39. Herndon LW, Brunner TM, Rollins JN: The glaucoma research foundation patient survey: patient understanding of glaucoma and its treatment. / Am J Ophthalmol 2006,141(1 Suppl):S22-7. CrossRef
  40. Abelson MB, Mroz M, Rosner SA, Dirks MS, Hirabayashi D: Multicenter, open-label evaluation of hyperemia associated with use of bimatoprost in adults with open-angle glaucoma or ocular hypertension. / Adv Ther 2003, 20:1-3. CrossRef
  41. Trattler W, Noecker RJ, Earl ML: A multicentre evaluation of the effect of patient education on acceptance of hyperemia associated with bimatoprost therapy for glaucoma or ocular hypertension. / Adv Ther 2008, 25:179-89. CrossRef
  42. The pre-publication history for this paper can be accessed here: http://www.biomedcentral.com/1471-2415/14/21/prepub
  
• 作者单位：Kaidi Wang (1)
  Li Xu (2)
  Zhilan Yuan (3)
  Ke Yao (4)
  Junmei Zhao (5)
  Liang Xu (6)
  Aiwu Fang (7)
  Mingzhi Zhang (8)
  Lingling Wu (9)
  Jian Ji (10)
  Jiamin Hou (11)
  Qing Liu (12)
  Xinghuai Sun (1)
  
  1. Eye & ENT Hospital, Shanghai Medical College, Fudan University, Fenyang Road 83, Shanghai, Xuhui District, 200031, China
  2. Department of Ophthalmology, the Fourth People’s Hospital of Shenyang, Shenyang, China
  3. Department of Ophthalmology, the People’s Hospital of Jiangsu, Nanjing, China
  4. Eye Center of the 2nd Affiliated Hospital, Medical College of Zhejiang University, Hangzhou, China
  5. Shanxi Eye Hospital, Taiyuan, China
  6. Beijing Institute of Ophthalmology, Beijing Tongren Hospital, Capital University of Medical Science, Beijing, China
  7. Eye Hospital, Wenzhou Medical College, Wenzhou, China
  8. Joint Shantou International Eye Center, Shantou University & the Chinese University of Hong Kong, Shantou, China
  9. Peking University Eye Center, Peking University Third Hospital, Beijing, China
  10. Eye Centre of Tianjin Medical University, Tianjin, China
  11. Eye Institute and Xiamen Eye Center of Xiamen University, Xiamen, China
  12. Allergan Information Consulting (Shanghai) Co., Ltd., Shanghai, China
  
• ISSN：1471-2415

文摘

Background To report the clinical outcomes in Chinese patients with primary open-angle glaucoma and ocular hypertension treated with bimatoprost 0.03% therapy. Methods Two hundred sixty-three Chinese patients with primary open-angle glaucoma and ocular hypertension who needed initial or additional intraocular pressure (IOP) lowering were recruited in this prospective, open-label, multicenter clinical study and were treated with bimatoprost 0.03%. Patients received bimatoprost 0.03% as initial, replacement or adjunctive IOP-lowering therapy, and follow-up visits were performed at week 1, and month 1 and 3 of the bimatoprost treatment. The efficacy outcome measure was the post-treatment IOP level. The safety outcome measures included the rate of medication-related symptoms, physical signs, reported adverse events, and the level of conjunctival hyperemia. Results Among 240 patients who could be categorized by pre-existing therapies and the bimatoprost therapy regimen in the study, IOP values observed in all medication conditions showed significant IOP reduction at all study visits compared with baseline. At 3 months, 8.0?±-.7 mmHg (32.0%) reduction in IOP was observed in treatment-naive patients after bimatoprost monotherapy; in the patients previously on various therapy regimens, 1.9?±-.8 mmHg (9.5%) to 6.4?±-.1 mmHg (24.8%) additional IOP lowering was achieved after switching to bimatoprost monotherapy or bimatoprost combination therapy. The most common adverse event was conjunctival hyperemia, mainly of trace and mild intensity. Conclusions Our results show that bimatoprost 0.03% was effective in lowering IOP with favorable safety in Chinese primary open-angle glaucoma and ocular hypertension patients.